Related references
Note: Only part of the references are listed.Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy
Nicoletta Colombo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
New, expanded, and modified use of approved antineoplastic agents in ovarian cancer
Maurie Markman
ONCOLOGIST (2007)
Ovarian cancer
Nicoletta Colombo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Management of platinum-sensitive recurrent ovarian cancer
Jacobus Pfisterer et al.
SEMINARS IN ONCOLOGY (2006)
Role of gemcitabine in ovarian cancer treatment
D. Lorusso et al.
ANNALS OF ONCOLOGY (2006)
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: An integrated analysis
DK Armstrong et al.
ONCOLOGIST (2005)
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma:: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study
AJ González-Martín et al.
ANNALS OF ONCOLOGY (2005)
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
AN Gordon et al.
GYNECOLOGIC ONCOLOGY (2004)
Cancer of the ovary
SA Cannistra
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Ovarian cancer: Review of the National Institute for Clinical Excellence (NICE) guidance recommendations
SRD Johnston
CANCER INVESTIGATION (2004)
Topotecan dosing guidelines in ovarian cancer: Reduction and management of hematologic toxicity
DK Armstrong
ONCOLOGIST (2004)
A new therapeutical approach: Topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum
J Sehouli et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2003)
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy
J Sehouli et al.
ANNALS OF ONCOLOGY (2002)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
